Xposition S is an advanced sirolimus-eluting self-apposing stent, which is delivered by a clinically proven stent delivery system that closely replicates conventional stent implantation technique.

The delivery system has been developed based on the Cappella Peel Away technology that was acquired by the company less than a year ago.

STENTYS CEO and co-founder Gonzague Issenmann said: "This CE Marking represents a quantum leap in terms of product design as we now have a stent delivery system that mimics how a conventional stent is implanted, thereby paving the way to much faster adoption of the Self-Apposing technology by interventional cardiologists."

The approval will allow the company to sell the product in Europe and all other countries where the CE mark is accepted.

The company will officially launch the new coronary stent system at the EuroPCR conference, which will be held on 19 May 2015.

STENTYS also produces MiStent SES, a coronary DES whose new drug delivery mechanism is designed to match vessel response. It is available in Europe, the Middle East, Asia and Latin America.